<DOC>
	<DOC>NCT02833350</DOC>
	<brief_summary>This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate therapy (Cohort 1) or methotrexate and tumor necrosis factor (TNF) therapy (Cohort 2).</brief_summary>
	<brief_title>Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Have a diagnosis of adultonset RA as defined by the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria for RA RA disease activity by joint counts and laboratory markers of inflammation: greater than or equal to (&gt;=) 6 tender/painful joints on motion (68 joint count) and &gt;= 6 swollen joints (66 joint count) at both screening and Day 1 (randomization) For methotrexateinadequate response (IR) participants: must have had an inadequate response to methotrexate For TNFIR participants: must have had an inadequate response to 1 or 2 TNF inhibitors History of or current inflammatory joint disease other than RA or other systemic autoimmune disorder For methotrexateIR participants: History of treatment with any TNF inhibitor, including biosimilar equivalents For all participants: Previous treatment with any nonTNF inhibitor biologic diseasemodifying antirheumatic drugs (DMARDs) (including biosimilar equivalents), tofacitinib, other Janus kinase inhibitor(s), or alkylating agents Evidence of serious uncontrolled concomitant cardiac, neurologic, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal (GI) disease Evidence of chronic and/or active hepatitis B or C Women who are pregnant, nursing (breast feeding), or intending to become pregnant during the study or within 60 days after completion of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>